Tag: RNA therapeutics
-
Lp(a) lowering is already a gold rush — but every road runs to one readout, and the events have not been read
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Lipoprotein(a) lowering is already a mature commercial field: three injectable siRNA/ASO agents are in large cardiovascular-outcome Phase 3 trials at roughly 90%+ Lp(a) reduction, an oral…
Uthando Nethemba 